PIONEER: avapritinib versus placebo in indolent systemic mastocytosis
A low dose of the KIT inhibitor avapritinib eased the itching, flushing, gut and bone symptoms of indolent systemic mastocytosis more than placebo, the first drug shown to do so in a randomised trial.
Overview
Randomised double-blind phase 2 trial of 212 patients with indolent systemic mastocytosis and moderate to severe symptoms despite best supportive care, assigned to avapritinib 25 mg daily or placebo for 24 weeks.
The total symptom score fell by 15.6 points with avapritinib against 9.2 with placebo, with parallel falls in serum tryptase, KIT D816V allele burden and bone marrow mast cells; adverse events were mostly mild. The FDA approved avapritinib for indolent systemic mastocytosis in 2023.
- Total symptom score reduced by 15.6 points with avapritinib versus 9.2 with placebo at 24 weeks.
- Serum tryptase, KIT D816V allele fraction and marrow mast cell burden fell with avapritinib.
Patients with indolent systemic mastocytosis whose symptoms persist on antihistamines and mast cell stabilisers now have a disease-modifying option.
- Symptom score is subjective and the placebo response was substantial.
- Long-term safety of continuous KIT inhibition in a non-fatal disease is still being followed.
Similar pages
not linked directly; found by shared links- Trial(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo
Shares Avapritinib, Indolent and smouldering systemic mastocytosis.
- CancerAdvanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
Shares Avapritinib, Indolent and smouldering systemic mastocytosis.
- CancerSystemic mastocytosis
Shares Avapritinib, Indolent and smouldering systemic mastocytosis.